324 related articles for article (PubMed ID: 30993426)
1. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
Ferro M; Di Lorenzo G; Vartolomei MD; Bruzzese D; Cantiello F; Lucarelli G; Musi G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; Gabriele A; Del Giudice F; Damiano R; Perri F; Perdona S; Verze P; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Autorino R; Crisan N; Farhan ARA; Battaglia M; Russo GI; Ieluzzi V; Morgia G; De Placido P; Terracciano D; Cimmino A; Scafuri L; Mirone V; De Cobelli O; Shariat S; Sonpavde G; Buonerba C
World J Urol; 2020 Jan; 38(1):143-150. PubMed ID: 30993426
[TBL] [Abstract][Full Text] [Related]
2. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
3. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.
Shahin O; Thalmann GN; Rentsch C; Mazzucchelli L; Studer UE
J Urol; 2003 Jan; 169(1):96-100; discussion 100. PubMed ID: 12478112
[TBL] [Abstract][Full Text] [Related]
5. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
[TBL] [Abstract][Full Text] [Related]
6. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
Brake M; Loertzer H; Horsch R; Keller H
Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
[TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
9. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
Hurle R; Losa A; Manzetti A; Lembo A
Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.
Choi J; Kim KH; Kim HS; Yoon HS; Kim JH; Kim JW; Lee YS; Choi SY; Chang IH; Ko YH; Song W; Jeong BC; Nam JK
Investig Clin Urol; 2024 May; 65(3):248-255. PubMed ID: 38714515
[TBL] [Abstract][Full Text] [Related]
11. Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guérin.
Trépanier G; Nykopp T; Rosebush-Mercier R; Gris T; Fadel J; Black PC; Toren P
Clin Genitourin Cancer; 2024 Apr; 22(2):354-359.e1. PubMed ID: 38185610
[TBL] [Abstract][Full Text] [Related]
12. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
13. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
15. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
[TBL] [Abstract][Full Text] [Related]
18. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
